Table 3.
Mean tumor marker expression score for BCL6, BLIMP1, LMO2 and CD30 among others by tumor EBV infection status.
| DLBCL EBV infection status | BCL6 | BLIMP1 | LMO2 | CD30 |
|---|---|---|---|---|
|
| ||||
| Tumor marker scorea, mean (sd) | ||||
| EBV− (n=48) | 1.78 (1.34) | 0.09 (0.36) | 2.33 (1.55) | 0.62 (1.27) |
| EBV+ (n=22) | 0.55 (1.10) | 0.77 (1.27) | 1.09 (1.02) | 1.76 (1.73) |
| p-valueb | <0.001 | 0.003 | 0.003 | <0.001 |
|
| ||||
| BCL2 | BAX | Cyclin D2 | Cyclin E | |
|
|
||||
| EBV− | 1.83 (1.34) | 2.89 (1.37) | 0.02 (0.15) | 1.24 (1.37) |
| EBV+ | 1.33 (1.24) | 2.05 (1.53) | 0.05 (0.21) | 1.64 (1.33) |
| p-valueb | 0.231 | 0.016 | 0.598 | 0.239 |
|
| ||||
| Ki-67 | FOXP1 | P53 | Survivin | |
|
|
||||
| EBV− | 2.10 (0.79) | 1.25 (1.25) | 0.54 (1.15) | 2.91 (1.43) |
| EBV+ | 2.29 (1.64) | 0.91 (1.27) | 0.77 (1.02) | 2.71 (1.45) |
| p-valueb | 0.534 | 0.326 | 0.110 | 0.342 |
|
| ||||
| P27 | MMP9 | GAL3 | SKP2 | |
|
|
||||
| EBV− | 0.52 (0.80) | 1.82 (1.66) | 1.58 (1.44) | 0.44 (1.03) |
| EBV+ | 0.64 (0.73) | 2.24 (1.70) | 1.33 (1.43) | 0.41 (0.91) |
| p-valueb | 0.353 | 0.495 | 0.345 | 0.632 |
|
| ||||
| PKC-beta 2 | MUM1 | cMYC | CD43 | |
|
|
||||
| EBV− | 2.52 (1.79) | 1.52 (1.50) | 1.46 (1.50) | 0.89 (1.52) |
| EBV+ | 3.00 (1.45) | 2.50 (1.41) | 1.73 (1.49) | 1.52 (1.89) |
| p-valueb | 0.218 | 0.012 | 0.598 | 0.278 |
|
| ||||
| CD10 | CD44 | CD21 | ||
|
|
||||
| EBV− | 1.08 (1.40) | 2.81 (1.28) | 1.12 (0.15) | |
| EBV+ | 1.00 (1.35) | 2.71 (1.19) | 0 | |
| p-valueb | 0.945 | 0.602 | 0.493 | |
a
Tumor marker score 0=0–9%, 1=10–24%, 2=25–49%, 3=50–74% and 4= ≥75% of DLBCL cells stained positive for the marker.
b
p-value derived from Pearson’s correlation coefficient statistics. Significance level for p-value <0.10 after adjustment for multiple comparison is 0.004 [0.10/23 (number of markers examined)=0.004].